Research progress of sacubitril/valsartan in the treatment of cardiovascular diseases
Author:
Affiliation:

1.Department of Cardiovascular Medicine, Second Clinical School of Medicine, Shanxi Medical University, ;2.Department of Cardiovascular Medicine, Second Hospital of Shanxi Medical University, ;3.Department of Internal Medicine, Central Hospital of Xinghualing District of Taiyuan City, Taiyuan, Shanxi 030000, China)

Clc Number:

R54

  • Article
  • | |
  • Metrics
  • |
  • Reference
  • |
  • Related
  • |
  • Cited by
  • | |
  • Comments
    Abstract:

    Sacubitril/valsartan is the first angiotensin receptor neprilysin inhibitor that simultaneously inhibits neprilysin and blocks angiotensin receptor. “Guidelines for the Diagnosis and Treatment of Heart Failure in China 2018” made a class Ⅰ recommendation for sacubitril/valsartan that surpassed European and American guidelines. 2021 US Food And Drug Administration approves sacubitril/valsartan for the treatment of heart failure patients with normal ejection fraction. Numerous studies have shown beneficial effects of sacubitril/valsartan in patients with heart failure, myocardial infarction, arrhythmia, hypertension, chronic kidney disease and diabetes. This article reviews the application progress of sacubitril/valsartan in the treatment of cardiovascular disease and related diseases.

    Reference
    Related
    Cited by
Get Citation

ZHANG Yue, BIAN Yunfei, GUO Xunan, YANG Zhimei. Research progress of sacubitril/valsartan in the treatment of cardiovascular diseases[J]. Editorial Office of Chinese Journal of Arteriosclerosis,2022,30(12):1071-1076.

Copy
Share
Article Metrics
  • Abstract:
  • PDF:
  • HTML:
  • Cited by:
History
  • Received:March 19,2021
  • Revised:October 08,2021
  • Online: December 13,2022
Article QR Code